2 research outputs found

    The binding of the small heat-shock protein αB-crystallin to fibrils of α-synuclein is driven by entropic forces.

    No full text
    Molecular chaperones are key components of the cellular proteostasis network whose role includes the suppression of the formation and proliferation of pathogenic aggregates associated with neurodegenerative diseases. The molecular principles that allow chaperones to recognize misfolded and aggregated proteins remain, however, incompletely understood. To address this challenge, here we probe the thermodynamics and kinetics of the interactions between chaperones and protein aggregates under native solution conditions using a microfluidic platform. We focus on the binding between amyloid fibrils of α-synuclein, associated with Parkinson's disease, to the small heat-shock protein αB-crystallin, a chaperone widely involved in the cellular stress response. We find that αB-crystallin binds to α-synuclein fibrils with high nanomolar affinity and that the binding is driven by entropy rather than enthalpy. Measurements of the change in heat capacity indicate significant entropic gain originates from the disassembly of the oligomeric chaperones that function as an entropic buffer system. These results shed light on the functional roles of chaperone oligomerization and show that chaperones are stored as inactive complexes which are capable of releasing active subunits to target aberrant misfolded species.The research leading to these results has received funding from the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007- 2013) through the ERC grant PhysProt (agreement n◦ 337969) (TS, TPJK). Furthermore, we acknowledge financial support from the Marie Curie fellowship scheme for career development (PA), EPSRC (EP/J01835x/1) (OT,JLPB), BBSRC, the Cambridge Commonwealth, European and International Trust (MMJB), the NIHOxford Cambridge Scholars Programme (MMJB), the Oppenheimer Fellowship (THW), the Frances and Augustus Newman Foundation (TPJK), the Wellcome Trust (094425/Z/10/Z) (CMD, MV, TPJK), the UK Research and Innovation Future Leaders Fellowship (MR/S033947/1) (FAA) and the Alzheimer’s Society, UK (511) (FAA). Furthermore, we thank Eva Klimont for protein preparation and Alexander Büll for helpful discussion
    corecore